ECHO IQ LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.135 AUD | 0.00% |
|
+8.00% | -20.59% |
| 01:45am | Echo IQ Launches Heart Failure Detection Study with AI | MT |
| May. 07 | Echo IQ Lodges US FDA Application for EchoSolv Market Clearance; Shares Fall 4% | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 251K 167K | Sales 2023 | 107K 71.44K | Capitalization | 70.84M 47.15M |
|---|---|---|---|---|---|
| Net income 2022 | -5M -3.33M | Net income 2023 | -7M -4.66M | EV / Sales 2022 | 175 x |
| Net cash position 2022 | 2.41M 1.6M | Net cash position 2023 | 3.28M 2.18M | EV / Sales 2023 | 629 x |
| P/E ratio 2022 |
-7.54
x | P/E ratio 2023 |
-8.56
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.46% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +8.00% | ||
| Current month | +22.73% | ||
| 1 month | +35.00% | ||
| 3 months | +12.50% | ||
| 6 months | -20.59% | ||
| Current year | -20.59% |
1 week
0.13
0.16
1 month
0.100.16
Current year
0.100.17
1 year
0.100.23
3 years
0.090.23
5 years
0.010.23
10 years
0.011.15
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Grover
CEO | Chief Executive Officer | - | 19-05-23 |
Seán Bryceland
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-28 |
Philip Woolff
COO | Chief Operating Officer | - | 21-11-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Picton
BRD | Director/Board Member | - | 21-10-19 |
Steven Formica
BRD | Director/Board Member | 64 | 18-07-01 |
| - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 0.135 | 0.00% | 614 |
| 24-05-20 | 0.135 | 0.00% | 234,187 |
| 24-05-17 | 0.135 | -3.57% | 445,338 |
| 24-05-16 | 0.14 | 0.00% | 1,231,367 |
| 24-05-15 | 0.14 | +12.00% | 1,159,371 |
Delayed Quote Australian S.E., May 21, 2024 at 12:27 am EDT
More quotes
EchoIQ Limited is an Australia-based artificial intelligence (AI) and medical technology company. It uses AI-driven technology and proprietary software to improve decision-making in cardiology. The principal activity of the Company is the development of AI products for cardiovascular care. The Company operates through two segments: Echo IQ and Houston We Have Software. The Echo IQ segment is engaged in developing products and services in medical technology. The Houston We Have Software segment offers products and services across other sectors. Its EchoSolv product allows users to assess echocardiographic studies against diagnostic guidelines for structural heart conditions. EchoSolv automatically identifies patients at risk of structural heart disease. EchoSolv improves the standard clinical workflow associated with diagnosis and treatment. The first two conditions addressed by the product are Aortic Stenosis and Mitral Regurgitation.
Calendar
2024-08-28
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 44.64M | |
| +9.06% | 33.93B | |
| +19.58% | 8.09B | |
| +32.48% | 4.3B | |
| -18.34% | 1.41B | |
| -26.12% | 1.31B | |
| -33.58% | 1.15B | |
| +11.82% | 1B | |
| -33.89% | 924M | |
| -22.36% | 676M |
- Stock Market
- Equities
- EIQ Stock